It Seems CR Bard Incorporated (NYSE:BCR) Will Go Down. Just Reported More Shorted Shares

December 8, 2017 - By Dolores Ford

 It Seems CR Bard Incorporated (NYSE:BCR) Will Go Down. Just Reported More Shorted Shares

Investors sentiment decreased to 0.58 in Q2 2017. Its down 0.30, from 0.88 in 2017Q1. It turned negative, as 99 investors sold C. R. Bard, Inc. shares while 273 reduced holdings. 103 funds opened positions while 111 raised stakes. 55.14 million shares or 10.97% less from 61.93 million shares in 2017Q1 were reported.
Nuveen Asset Management Llc reported 2,048 shares. Schwab Charles Inv Management reported 0.07% of its portfolio in C. R. Bard, Inc. (NYSE:BCR). 15,158 are held by Strategy Asset Managers Ltd Liability Company. Royal Bancshares Of Canada invested in 0.02% or 114,843 shares. Ig Invest Mgmt Ltd invested in 9,769 shares or 0.02% of the stock. Loring Wolcott & Coolidge Fiduciary Limited Liability Partnership Ma accumulated 1,375 shares. Profund Advsrs Llc holds 0.05% of its portfolio in C. R. Bard, Inc. (NYSE:BCR) for 3,146 shares. Fuller And Thaler Asset Mgmt invested in 600 shares. Howland Ltd Liability Corporation stated it has 0.08% in C. R. Bard, Inc. (NYSE:BCR). Boston Family Office Ltd has 4,500 shares for 0.17% of their portfolio. Kames Public Ltd Co has invested 0% in C. R. Bard, Inc. (NYSE:BCR). Price T Rowe Assocs Md, a Maryland-based fund reported 130,633 shares. Condor Mgmt holds 0.31% or 4,641 shares. 197,500 are held by Gabelli Funds Limited Liability. New York-based Arrow has invested 0.01% in C. R. Bard, Inc. (NYSE:BCR).

The stock of CR Bard Incorporated (NYSE:BCR) registered an increase of 8.9% in short interest. BCR’s total short interest was 1.22 million shares in December as published by FINRA. Its up 8.9% from 1.12M shares, reported previously. With 414,400 shares average volume, it will take short sellers 3 days to cover their BCR’s short positions. The short interest to CR Bard Incorporated’s float is 1.7%.

The stock increased 0.06% or $0.19 during the last trading session, reaching $332.07. About 569,187 shares traded or 15.70% up from the average. C. R. Bard, Inc. (NYSE:BCR) has risen 40.70% since December 8, 2016 and is uptrending. It has outperformed by 24.00% the S&P500.

C. R. Bard, Inc., together with its subsidiaries, designs, makes, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company has market cap of $24.21 billion. The firm offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and a range of minimally invasive devices for the treatment of peripheral vascular and end-stage renal diseases. It has a 43.8 P/E ratio. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for the treatment of prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal procedures; surgical slings and pelvic floor repair products; catheter stabilization devices; and products for therapeutic hypothermia.

C. R. Bard, Inc. (NYSE:BCR) Ratings Coverage

Among 15 analysts covering CR Bard (NYSE:BCR), 4 have Buy rating, 0 Sell and 11 Hold. Therefore 27% are positive. CR Bard has $337 highest and $190 lowest target. $261.17’s average target is -21.35% below currents $332.07 stock price. CR Bard had 32 analyst reports since August 27, 2015 according to SRatingsIntel. Citigroup maintained the shares of BCR in report on Wednesday, July 27 with “Buy” rating. The rating was maintained by Barclays Capital on Wednesday, July 27 with “Equalweight”. The firm has “Market Perform” rating by Wells Fargo given on Wednesday, April 26. Jefferies maintained C. R. Bard, Inc. (NYSE:BCR) rating on Wednesday, July 27. Jefferies has “Hold” rating and $237 target. The stock of C. R. Bard, Inc. (NYSE:BCR) earned “” rating by Raymond James on Wednesday, April 26. The stock of C. R. Bard, Inc. (NYSE:BCR) has “Overweight” rating given on Tuesday, January 3 by Morgan Stanley. Needham maintained the stock with “Hold” rating in Friday, September 22 report. The firm has “Sector Weight” rating given on Thursday, August 27 by KeyBanc Capital Markets. BMO Capital Markets maintained the stock with “Buy” rating in Wednesday, April 12 report. As per Thursday, March 17, the company rating was initiated by Nomura.

Another recent and important C. R. Bard, Inc. (NYSE:BCR) news was published by which published an article titled: “What Jabil’s new director signals about the company’s future” on November 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: